Patents Examined by Rayna B Rodriguez
-
Patent number: 9309193Abstract: Compounds of Formula (Ia) wherein R is a C6-C12 substituted or unsubstituted aryl, a C6-C12 substituted or unsubstituted heteroaryl, a C1-C6 substituted or unsubstituted alkyl or —NR?R?, Q is C(O), O, NR?, S, S(O)2, C(O)2 (CH2)p Y is C(O), O, NR?, S, S(O)2, C(O)2 (CH2)p Z is H or C1-C4 alkyl, R? is H, C(O), S(O)2, C(O)2, a C6-C12 substituted or unsubstituted aryl, a C6-C12 substituted or unsubstituted heteroaryl or a C1-C6 substituted or unsubstituted alkyl, when substituted, aryl, heteroaryl and alkyl are substituted with halogen, C6-C12 heteroaryl, —NR?R? or COOZ, which have diagnostic and therapeutic properties, such as the treatment and management of prostate cancer and other diseases related to NAALADase inhibition. Radiolabels can be incorporated into the structure through a variety of prosthetic groups attached at the X amino acid side chain via a carbon or hetero atom linkage.Type: GrantFiled: October 12, 2011Date of Patent: April 12, 2016Assignee: Molecular Insight Pharmaceuticals, Inc.Inventors: John W. Babich, Craig N. Zimmerman, Kevin P. Maresca
-
Patent number: 9271947Abstract: A method for reducing parasites in aquatic animals is provided. The method includes reducing a plurality of parasites infecting an aquatic animal by administrating to the aquatic animal a compound comprising propyl propane thiosulfonate (PTSO) having the formula R—SOa-S—R, where R represents n-propyl group (—CH2—CH2—CH3) and a is 2. In yet a different embodiment, a method for reducing a plurality of parasites infecting an aquatic animal includes administrating to the aquatic animal a compound comprising and propyl propane thiosulfinate (PTS) having the formula R—SOa-S—R, where R represents n-propyl group (—CH2—CH2—CH3) and a is 1. In even yet another embodiment, a method for preventing a plurality of parasites in aquatic animals is provided and includes administrating to an aquatic animal a compound including PTS. In a different embodiment, a method for preventing a plurality of parasites in aquatic animals is provided and includes administrating to an aquatic animal a compound including PTSO.Type: GrantFiled: October 1, 2013Date of Patent: March 1, 2016Assignee: Investfood, LLCInventors: Cristina Núñez Lechado, Alberto Baños Arjona, Enrique Guillamón Ayala, Adela Valero López, Ma Concepción Navarro Moll, Ana Sanz Rus
-
Patent number: 9260410Abstract: There is provided inter alia a compound of formula (I): wherein R1, J, Ar, L, X, R3 and R4 are as defined in the specification, for use in the treatment of inflammatory disorders.Type: GrantFiled: April 8, 2011Date of Patent: February 16, 2016Assignee: Respivert Ltd.Inventors: John King-Underwood, Kazuhiro Ito, Peter Strong, William Garth Rapeport, Catherine Elisabeth Charron, Peter John Murray, Jonathan Gareth Williams, Stuart Thomas Onions
-
Patent number: 9254284Abstract: The present invention relates to a compound of formula (I): The compound has apoptosis signal-regulating kinase (“ASK1”) inhibitory activity, and is thus useful in the treatment of diseases such as kidney disease, diabetic nephropathy and kidney fibrosis.Type: GrantFiled: April 16, 2014Date of Patent: February 9, 2016Assignee: Gilead Sciences, Inc.Inventor: Gregory Notte
-
Patent number: 9220716Abstract: The technology described herein is directed to methods and compositions for the treatment of proliferative vascular disorders, e.g. hemangioma. In some aspects, the methods and compositions described herein related to a mTOR inhibitor or nifedipine.Type: GrantFiled: July 26, 2012Date of Patent: December 29, 2015Assignee: Children's Medical Center CorporationInventors: Joyce Bischoff, Shoshana Greenberger
-
Patent number: 9174941Abstract: Disclosed herein are novel antioxidant inflammation modulators, including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds and compositions thereof are also provided.Type: GrantFiled: July 11, 2013Date of Patent: November 3, 2015Assignee: Reata Pharmaceuticals, Inc.Inventors: Eric Anderson, Gary L. Bolton, Bradley Caprathe, Xin Jiang, Chitase Lee, William H. Roark, Melean Visnick
-
Patent number: 9120801Abstract: Tricyclic indazole compound and its pharmaceutically acceptable salts of acid addition, use thereof, method and intermediates for preparing them, and a pharmaceutical composition containing them. The tricyclic indazole compound has the following general Formula (I): in which R1, R2, L1, L2, X1, X2, X3, X4, X5, Y, W, m, and n have the meanings stated in the description.Type: GrantFiled: March 4, 2011Date of Patent: September 1, 2015Assignee: AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A.Inventors: Maria Alessandra Alisi, Nicola Cazzolla, Guido Furlotti, Beatrice Garrone, Gabriele Magaro', Giorgina Mangano
-
Patent number: 9101573Abstract: The present invention relates to the field of medical treatments for diseases and disorders. More specifically, the present invention relates to the use of the lanthionine synthetase component C-like (LANCL) proteins as therapeutic targets for novel classes of anti-inflammatory, immune regulatory and antidiabetic drugs.Type: GrantFiled: May 4, 2011Date of Patent: August 11, 2015Assignee: VIRGINIA TECH INTELLECTUAL PROPERTIES, INC.Inventors: Josep Bassaganya-Riera, Pinyi Lu, Raquel Hontecillas
-
Patent number: 9089532Abstract: The invention relates to improved and stable pharmaceutical formulations of phenylalanine derivatives and the use thereof as urokinase inhibitors, particularly for the treatment of malignant tumors and tumoral metastases.Type: GrantFiled: September 20, 2005Date of Patent: July 28, 2015Assignee: Wilex AGInventors: Wolfgang Schmalix, Markus Bürgle, Klaus Koch
-
Patent number: 9089139Abstract: Agri-horticultural pest control compositions having outstanding control effect on pests, in particular, agri-horticultural pests, which comprise as active ingredients one or more 4-(3-butynyl)aminopyrimidine derivatives represented by the general formula [I], namely, where R1 is typically selected from among: a) phenyl c) —SiR5R6R7 (R5, R6, and R7 which may be the same or different represent a linear or branched alkyl having 1-6 carbon atoms, a linear or branched haloalkyl having 1-3 carbon atoms which is substituted by one halogen atom, a linear or branched cyanoalkyl having 1-3 carbon atoms which is substituted by one cyano group, and phenyl); d) hydropgen atom; R2 typically represents a hydrogen atom; R3 typically represents a hydrogen atom; R4 represents a hydrogen atom and one or more agri-horticultural pest control compounds selected from among agri-horticultural antimicrobial compounds, say, multi-site contact active compounds, nucleic acids synthesis inhibitory active compounds, mitosis and cellType: GrantFiled: December 27, 2011Date of Patent: July 28, 2015Assignee: SDS Biotech K. K.Inventors: Masaaki Sakai, Tomoaki Matsumura, Satohiro Midorikawa, Takashi Nomoto, Tomoko Muraki, Ryutaro Katsuki
-
Patent number: 9062056Abstract: Disclosed are small molecule inhibitors of the formula (I): and the pharmaceutical compositions thereof and processes of making the same. The compounds are useful in treating various diseases and conditions involving chymase.Type: GrantFiled: August 25, 2009Date of Patent: June 23, 2015Assignee: Boehringer Ingelheim International GmbHInventors: Michel Jose Emmanuel, Xin Guo, Jin Mi Kim, Ho Yin Lo, Peter Allen Nemoto, Kevin Chungeng Qian
-
Patent number: 9051331Abstract: The present invention relates to a series of substituted dihydro benzocycloalkyl-oxymethyl oxazolopyrimidinones of formula (I): Wherein n, R1, R2, R3, R4, R5 and R6 are as defined herein. This invention also relates to methods of making these compounds including novel intermediates. The compounds of this invention are modulators of metabotropic glutamate receptors (mGluR), particularly, mGluR2 receptor. Therefore, the compounds of this invention are useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of central nervous system disorders (CNS), including but not limited to acute and chronic neurodegenerative conditions, psychoses, cognition deficit disorders, convulsions, anxiety, depression, migraine, pain, sleep disorders and emesis.Type: GrantFiled: March 2, 2012Date of Patent: June 9, 2015Assignee: SanofiInventors: Rosy Sher, Raymond Walter Kosley, Jr.
-
Patent number: 9012677Abstract: The present invention relates to the discovery of new class of hydrolysable amino acid derivatives and absorbable polyester amides, polyamides, polyepoxides, polyureas and polyurethanes prepared therefrom. The resultant absorbable polymers are useful for drug delivery, tissue engineering, tissue adhesives, adhesion prevention, bone wax formulations, medical device coatings, stents, stent coatings, highly porous foams, reticulated foams, wound care, cardiovascular applications, orthopedic devices, surface modifying agents and other implantable medical devices. In addition, these absorbable polymers should have a controlled degradation profile.Type: GrantFiled: November 14, 2014Date of Patent: April 21, 2015Assignee: Bezwada Biomedical, LLCInventor: Rao S Bezwada
-
Patent number: 8980955Abstract: Replication protein A (RPA) is a single-strand DNA-binding protein with essential roles in DNA replication, recombination and repair. Small molecule inhibitors (SMIs) with the ability to disrupt RPA binding activity to ssDNA have been identified and assessed using both lung and ovarian cancer cell lines. Lung cancer cell lines demonstrated increased apoptotic cell death following treatment with the SMI MCI13E, with IC50 values of ˜5 ?M. The A2780 ovarian cancer cell line and the p53-null lung cancer cell line HI 299 were particularly sensitive to MCI13E treatment with IC50 values below 3 ?M. Sequential treatment with MCI13E and cisplatin resulted in synergism, suggesting that decreasing RPA's DNA binding activity via a SMI may disrupt RPA's role in cell cycle regulation. Thus, RPA SMIs hold the potential to be used as single agent chemotherapeutics or in combination with current chemotherapeutic regimens to increase their efficacy.Type: GrantFiled: September 19, 2011Date of Patent: March 17, 2015Assignee: Indiana University Research and TechnologyInventors: John J. Turchi, Richard Fitch
-
Patent number: 8962530Abstract: The invention relates to methods of treating inflammatory bowel disease in a subject. Methods of promoting intestinal barrier function as well as related compositions are also provided.Type: GrantFiled: June 26, 2008Date of Patent: February 24, 2015Assignees: Regents of the University of Colorado, The Brigham and Women's Hospital, Inc.Inventor: Sean P. Colgan
-
Patent number: 8937070Abstract: The present invention is directed to methods of inhibiting syk and/or JAK kinase activity, methods of inhibiting platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk and/or JAK kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma with compounds of the formula: and pharmaceutically acceptable tautomers, salts, or stereoisomers thereof.Type: GrantFiled: June 13, 2013Date of Patent: January 20, 2015Assignee: Portola Pharmaceuticals, Inc.Inventors: Shawn M. Bauer, Anjali Pandey
-
Patent number: 8933037Abstract: The invention refers to PDGFRbeta inhibitor for use in the antiproliferative treatment of T-cell lymphoma, in particular NHL, ALCL and PTCL.Type: GrantFiled: September 28, 2010Date of Patent: January 13, 2015Assignee: Medizinische Universitat WienInventors: Lukas Kenner, Daniela Laimer
-
Patent number: 8927728Abstract: Photoreactive DNA cleaving conjugate compounds are provided comprising a DNA cleaving moiety which comprises an aryl alkyne group and a polyfunctional pH-regulated DNA-binding moiety which comprises at least one or two amino groups.Type: GrantFiled: May 7, 2012Date of Patent: January 6, 2015Assignee: The Florida State University Research Foundation, Inc.Inventors: Igor Alabugin, Wang-Yong Yang, Saumya Roy, Kemal Kaya, Qing-Xiang Sang
-
Patent number: 8906933Abstract: The present invention is directed to novel dihydropyrimidin-2(1H)-one compounds useful as Neurokinin-3 (NK3) receptor antagonists, pharmaceutical compositions comprising such compounds, and methods of making and using the same.Type: GrantFiled: September 24, 2010Date of Patent: December 9, 2014Assignee: N30 Pharmaceuticals, Inc.Inventors: Xicheng Sun, Jian Qiu
-
Patent number: 8901341Abstract: The present invention relates to the discovery of new class of hydrolysable amino acid derivatives and absorbable polyester amides, polyamides, polyepoxides, polyureas and polyurethanes prepared therefrom. The resultant absorbable polymers are useful for drug delivery, tissue engineering, tissue adhesives, adhesion prevention, bone wax formulations, medical device coatings, stents, stent coatings, highly porous foams, reticulated foams, wound care, cardiovascular applications, orthopedic devices, surface modifying agents and other implantable medical devices. In addition, these absorbable polymers should have a controlled degradation profile.Type: GrantFiled: May 3, 2013Date of Patent: December 2, 2014Assignee: Bezwada Biomedical, LLCInventor: Rao S. Bezwada